Monograph Capital
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
RQ Bio
25 Jun 2026
RQ Bio raises a £86m Series A led by Frazier Life Sciences to develop long-acting antibody protection against seasonal influenza
RQ Bio is a UK-based biotechnology company developing long-acting monoclonal antibodies against seasonal influenza. Its lead programme, RQB01, is designed to deliver potent, broad-strain protection against influenza through a dual mechanism of action, targeting patients whose immune systems cannot rely on vaccination alone.
Elevara Medicines
22 Oct 2025
Elevara raises £50m Series A led by Forbion and Sofinnova Partners to develop therapies for rheumatoid arthritis
Elevara develops oral therapies for rheumatoid arthritis by targeting synovial fibroblasts rather than the immune system, aiming to improve remission rates in chronic inflammatory disease.
Monograph Capital
- 2(12 months)
- monograph.bio
- Update Information
More venture news
- 29 Jul 2026
LemonEdgeLemonEdge announced £16m Series A round led by Blackstone Innovations Investments for a fund accounting platform built for private markets
Series AFintech - 21 Jul 2026
HumanoidHumanoid unlocks £114m Series A led by Prime Movers Lab to deploy humanoid robots across industrial manufacturing and logistics
Series AIndustrial - 22 Jul 2026
ArrakisArrakis raises a £22m Series A led by Blossom Capital to install AI agents into industrial companies' mission-critical operations
Series AIndustrial
